Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes.

    ... were developed to treat patients with refractory immune thrombocytopenia but are now being investigated for the treatment of bone ...

    Research Article last updated 07/20/2018 - 5:15pm.

  2. Selective splenic artery embolization for the treatment of thrombocytopenia and hypersplenism in paroxysmal nocturnal hemoglobinuria

    ... The combination of thrombosis, splenomegaly, and thrombocytopenia (TST) is challenging because anticoagulants are indicated but thrombocytopenia may increase the bleeding risk. Splenectomy could alleviate ...

    Research Article last updated 07/20/2018 - 5:15pm.

  3. Thrombocytopenia in patients with myelodysplastic syndromes.

    ... Thrombocytopenia , common in leukemias and myelodysplastic syndromes ... purpura (ITP), and are being explored for the treatment of thrombocytopenia in MDS. Bone ...

    Research Article last updated 07/20/2018 - 5:14pm.

  4. Thrombopoiesis-stimulating agents and myelodysplastic syndromes

    ... Thrombocytopenia in patients with myelodysplastic syndromes (MDS) ... transformation and reduced overall survival. In addition, thrombocytopenia in MDS limits the tolerability and therapeutic efficacy of ...

    Research Article last updated 07/20/2018 - 5:15pm.

  5. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.

    ... BACKGROUND: In myelodysplastic syndromes , thrombocytopenia is associated with mortality, but treatments in this ... receptor agonist, might be effective in improving thrombocytopenia in lower-risk myelodysplastic syndromes and severe thrombocytopenia. METHODS: EQoL-MDS was a single-blind, randomised, ...

    Research Article last updated 02/21/2017 - 9:49am.

  6. Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic Syndromes

    ... years, mainly at the expense of neutropenia and thrombocytopenia in the first courses of therapy. At present, the optimal ... response, and 50% incidence of grade 3 and 4 neutropenia and thrombocytopenia compared to del(5q) patients. Recent data suggest that the ...

    Research Article last updated 07/20/2018 - 5:14pm.

  7. Immunosuppressive therapy for transplant-ineligible aplastic anemia patients

    ... infection and hemorrhage due to neutropenia and thrombocytopenia and suffer from symptoms of anemia. The main treatment ...

    Research Article last updated 07/20/2018 - 5:15pm.

  8. Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations.

    ... therapy or for patients with lower-risk MDS who have thrombocytopenia or neutropenia or have anemia that is ...

    Research Article last updated 07/20/2018 - 5:15pm.

  9. Clinical presentation, diagnosis, and prognosis of myelodysplastic syndromes

    ... degrees of anemia , neutropenia , and thrombocytopenia , and at presentation can range from indolent to life ...

    Research Article last updated 07/20/2018 - 5:14pm.

  10. Myelodysplastic syndromes: a challenging disease for patients and physicians

    ... high risk of rapidly developing neutropenia and thrombocytopenia . Several promising drugs are currently under investigation ...

    Research Article last updated 07/20/2018 - 5:14pm.